The Effect of Exogenous Glucagon-like Peptide 2 on Cholecystokinin-induced Gallbladder Emptying
Sponsor: The Novo Nordisk Foundation Center for Basic Metabolic Research
Listed as NCT04651868, this NA trial focuses on Gallbladder and remains completed. Sponsored by The Novo Nordisk Foundation Center for Basic Metabolic Research, it has been updated 6 times since 2020, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
6 versions recorded-
Jan 2025 — Present [monthly]
Completed NA
Status: Active Not Recruiting → Completed
-
Sep 2024 — Jan 2025 [monthly]
Active Not Recruiting NA
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting NA
-
Mar 2023 — Jul 2024 [monthly]
Active Not Recruiting NA
Status: Unknown Status → Active Not Recruiting
-
Jan 2023 — Mar 2023 [monthly]
Unknown Status NA
Status: Not Yet Recruiting → Unknown Status
▶ Show 1 earlier version
-
Jan 2021 — Jan 2023 [monthly]
Not Yet Recruiting NA
First recorded
Dec 2020
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- The Novo Nordisk Foundation Center for Basic Metabolic Research
- University Hospital, Gentofte, Copenhagen
For direct contact, visit the study record on ClinicalTrials.gov .